Evidence map›Paper›PMID 32516736›Full record

ArticleMolecular therapy. Nucleic acids2020

YAP1 Inhibition in HUVECs Is Associated with Released Exosomes and Increased Hepatocarcinoma Invasion and Metastasis.

Yan Li, Xiaodong Zhang, Qianqian Zheng, Yijun Zhang, Yingbo Ma, Chen Zhu, Liang Yang, Xueqiang Peng, Qi Wang, Biao Wang and 3 more

RetractedOpen access · goldAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Yan LiDepartment of General Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang 110032, China; Department of Radiation Oncology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.
Xiaodong ZhangGeneral Surgery Department, Beijing Friendship Hospital, Capital Medical University, Beijing, China; National Clinical Research Center for Digestive Diseases, Beijing, China.
Qianqian ZhengDepartment of Pathophysiology, College of Basic Medical Science, China Medical University, Shenyang, China.
Yijun ZhangDepartment of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Yingbo MaDepartment of General Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang 110032, China.
Chen ZhuDepartment of Neurosurgery, The First Hospital of China Medical University, Shenyang, China.
Liang YangDepartment of General Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang 110032, China.
Xueqiang PengDepartment of General Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang 110032, China.
Qi WangDepartment of Geriatrics, The First Affiliated Hospital of China Medical University, Shenyang, China.
Biao WangDepartment of Biochemistry and Molecular Biology, Academy of life sciences of China Medical University, Shenyang, China.
Xin MengDepartment of Biochemistry and Molecular Biology, Academy of life sciences of China Medical University, Shenyang, China.
Hangyu LiDepartment of General Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang 110032, China. Electronic address: sj_lihangyu@sina.com.
Jingang LiuDepartment of General Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang 110032, China. Electronic address: liujg0347@126.com.
China Medical University · CNFourth Affiliated Hospital of China Medical University · CNBeijing Friendship Hospital · CNFirst Hospital of China Medical University · CNJinzhou Medical University · CNSun Yat-sen University Cancer Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma is one of the most common gastrointestinal malignancies. Anti-angiogenesis therapies have recently demonstrated promise in the treatment of malignancies, although early treatment benefits may be accompanied by metastasis over time. Additional and more effective anti-angiogenic treatment modalities are therefore needed. We previously found that Yes-associated protein 1 (YAP1) expression is increased in hepatocellular carcinoma (HCC), particularly around tumor-associated blood vessels, suggesting a role in angiogenesis. The YAP1 inhibitor verteporfin is presently in anti-angiogenic clinical trials for the treatment of various cancers. Depleted YAP1 from vascular endothelial cells effectively reduced proliferation and tube formation, validating its utility as an anti-angiogenesis target. We also showed that YAP1 depletion or inhibition in vascular endothelial cells leads to increased release of exosomes containing the long non-coding RNA (lncRNA) MALAT1 into the tumor microenvironment. Direct exosomal transfer of MALAT1 to hepatic cells leads to increased hepatic cell invasion and migration via activation of extracellular signal-regulated kinase 1/2 (ERK1/2) signaling. These observations may explain the occurrence of distant tumor metastasis with YAP1-associated anti-angiogenic therapy over time. It provides insight into new pathways and treatment paradigms that may be targeted to increase the long-term success of anti-angiogenic therapies.

Identifiers

PMID32516736
PMCPMC7281784
OpenAlexW3026988274

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.